Physician profile
Michael Bacon
NPI 1184165425
$3,159.14
in general payments reported to CMS, 2019-2025
28 companies · $1,202 in 2025
The $1,202 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.16 · 2020: $69.52 · 2021: $428 · 2022: $13.82 · 2023: $368 · 2024: $1,038 · 2025: $1,202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,608.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $777.59 | 2021-2025 | Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $465.45 | 2020-2025 | Farxiga |
| Lilly USA, LLC | $219.70 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $206.42 | 2021-2025 | Arexvy, Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $187.32 | 2025 | Caplyta |
| Exact Sciences Corporation | $181.77 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $161.71 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $146.86 | 2024-2025 | Xifaxan, Trulance |
| Supernus Pharmaceuticals, INC. | $140.83 | 2024-2025 | Qelbree |
| Amgen INC. | $131.25 | 2023-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $75.02 | 2019-2025 | Ozempic, Wegovy |
| Axsome Therapeutics, INC. | $55.49 | 2025 | Auvelity |
| Astellas Pharma US INC | $51.16 | 2024-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.58 | 2020-2021 | |
| Corium, LLC | $41.39 | 2023-2025 | Azstarys |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $29.79 | 2024-2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $29.60 | 2025 | |
| Janssen Pharmaceuticals, INC | $29.14 | 2021 | |
| Daiichi Sankyo INC. | $28.37 | 2019-2022 | |
| Abiomed | $26.66 | 2023 | Impella |
| Dexcom, INC. | $22.25 | 2025 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $19.52 | 2024 | Yupelri |
| Vanda Pharmaceuticals INC. | $19.05 | 2025 | Fanapt |
| Sanofi-Aventis U.S. LLC | $18.38 | 2021 | |
| Allergan, INC. | $13.93 | 2020 | |
| Eisai INC. | $13.72 | 2021 | |
| Circassia INC. | $12.97 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bacon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.